Canada - English - Health Canada

pharmascience inc - ciclopirox - solution - 8% - ciclopirox 8% - hydroxypyridones

Canada - English - Health Canada

apotex inc - ciclopirox - solution - 8% - ciclopirox 8% - hydroxypyridones

Canada - English - Health Canada

taro pharmaceuticals inc - ciclopirox - solution - 8% - ciclopirox 8% - hydroxypyridones

Canada - English - Health Canada

sterimax inc - ciclopirox - solution - 8% - ciclopirox 8% - hydroxypyridones

Ireland - English - HPRA (Health Products Regulatory Authority)

glaxosmithkline (ireland) limited - ciclopirox olamine - shampoo - 15 milligram(s)/gram - other antifungals for topical use; ciclopirox

New Zealand - English - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - ciclopirox olamine 1%{relative} - topical cream - 1% w/w - active: ciclopirox olamine 1%{relative}

New Zealand - English - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - ciclopirox olamine 1%{relative} - topical solution - 1% w/v - active: ciclopirox olamine 1%{relative}

Ireland - English - HPRA (Health Products Regulatory Authority)

lexon pharmaceuticals (ireland) limited - ciclopirox olamine - shampoo - other antifungals for topical use; ciclopirox

United States - English - NLM (National Library of Medicine)

bausch health us, llc - ciclopirox (unii: 19w019zdrj) (ciclopirox - unii:19w019zdrj) - ciclopirox 10 mg in 0.96 ml - loprox® (ciclopirox) shampoo, 1% is indicated for the topical treatment of seborrheic dermatitis of the scalp in adults. none. teratogenic effects: pregnancy category b there are no adequate or well-controlled studies in pregnant women. therefore, loprox shampoo should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. oral embryofetal developmental studies were conducted in mice, rats, rabbits, and monkeys. ciclopirox or ciclopirox olamine was orally administered during the period of organogenesis. no maternal toxicity, embryotoxicity or teratogenicity were noted at the highest doses of 77, 125, 80, and 38.5 mg/kg/day ciclopirox in mice, rats, rabbits, and monkeys, respectively (approximately 13, 42, 54, and 26 times the maximum recommended human dose based on body surface area comparisons, respectively). dermal embryofetal developmental studies were conducted in rats and rabbits with ciclopirox olamine dissolved in peg 400. ciclopirox olamine was topically adm

United States - English - NLM (National Library of Medicine)

e. fougera & co. a division of fougera pharmaceuticals inc. - ciclopirox (unii: 19w019zdrj) (ciclopirox - unii:19w019zdrj) - none. teratogenic effects: pregnancy category b there are no adequate or well-controlled studies in pregnant women. therefore, ciclopirox shampoo should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. oral embryofetal developmental studies were conducted in mice, rats, rabbits and monkeys. ciclopirox or ciclopirox olamine was orally administered during the period of organogenesis. no maternal toxicity, embryotoxicity or teratogenicity were noted at the highest doses of 77, 125, 80 and 38.5 mg/kg/day ciclopirox in mice, rats, rabbits and monkeys, respectively (approximately 13, 42, 54 and 26 times the maximum recommended human dose based on body surface area comparisons, respectively). dermal embryofetal developmental studies were conducted in rats and rabbits with ciclopirox olamine dissolved in peg 400. ciclopirox olamine was topically administered during the period of organogenesis. no maternal toxicity, embryotoxicity or teratogenicity were noted at the hig